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Executive Summary 
 
An Overview  
 
The evaluation panel was very impressed with the excellent progress in the cancer control system 
in Ireland since the publication of “A Strategy for Cancer Control in Ireland” in 2006.  
 
Major improvements have been made across the whole spectrum of the patient journey from 
Prevention to End-of-Life care. A major achievement of the National Cancer Control Programme 
(NCCP) is that cancer services are now centralized in 8 designated Cancer Centers established in 
4 networks. This has led to major (and positive) changes in how cancer treatment is delivered 
with high volume multidisciplinary cancer services in diagnostics, surgery, radiation oncology 
and medical oncology. National Tumour Groups have been developed and produced 
comprehensive, succinct and evidence based guidelines for the management of many clinical 
conditions.  
 
The various policies and strategies around cancer prevention developed during the past 7 years 
are excellent and these should be continued and incorporated into the next cancer strategy. The 
evaluation panel was impressed with the national screening programmes for breast, cervical and 
bowel cancer and also noted that there appears to be excellent integration with diagnostic and 
surgical services. 
 
There has been significant progress in the area of early cancer diagnosis with the development of 
rapid access clinics, with electronic GP referral, in breast, lung and prostate and the 
implementation of three national screening programmes. National referral guidelines and 
pathways have been developed in multiple cancers. The evaluation panel was also very 
impressed by the progress to date of the National Quality Assurance Programmes in 
Histopathology, Endoscopy and Radiology. 
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Ongoing research is a key component of all high functioning cancer systems and the panel noted 
the breadth of clinical studies available to patients through ICORG and incremental progress 
made in terms of accrual to clinical trials.  
The most significant factor that contributed to success in driving change in the cancer control 
system was the leadership of the NCCP. As pointed out by the World Health Organization, 
proficient management is needed to integrate these activities into a coherent programme:  
 
“Key to competent management is the leadership of the programme, who should be 
facilitative, participatory and empowering in how vision and goals are carried out.”   
 
Overall, the evaluation panel believes that the NCCP has done a magnificent job in driving 
positive change in the cancer system. Looking to the future, we would stress that we believe that 
the NCCP should continue in its current role overseeing the Irish cancer system.  
 
This will be especially important as over the next decade there will be a major growth in 
incidence of cancer and demand for cancer services (27% projected increase in incidence from 
2015 to 2025).  Also, this is important in the context of acute hospital services being reorganized 
into hospital groups. With regionalization of acute care delivery, attention is needed to ensure the 
cancer control system evolves appropriately.  We believe that the cancer system would continue 
to benefit from leadership at a national level.  
 
Finally we would suggest the development of a publicly reported cancer system quality index 
based on the various components of Quality of Care, as described by the U.S. Institute of 
Medicine and contained in the National Standards for Safer Better Healthcare in Ireland. This is 
critical if the vision of the 2006 Cancer Control Strategy that “Ireland will have a system of 
cancer control which will reduce our cancer incidence, morbidity and mortality rates relative to 
other EU-15 countries” is to be achieved. 
 
Despite the progress over the past 7 years we believe there are a number of key areas that require 
attention and these are outlined hereafter: 
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Key Areas that Require Attention 
 
i. Legislative/Structural issues 
 
- Mandatory notification of cancer diagnosis should be introduced.  
- Introduction of a unique patient identifier (as planned in the Health Identification Act 
2014).   
- Information provided to hospital quality of care committees and other designated 
quality of care committees that deal with quality improvement should be shielded 
from disclosure in legal proceedings, as is done in many other jurisdictions. This 
legislative protection  should be designed to encourage health professionals to share 
information and hold open discussions to improve patient care, without fear that the 
information will be used against them. Under such legislation, information that deals 
with quality improvement would be shielded from disclosure in legal proceedings. 
However, the legal protections for quality of care information should be designed so 
that it cannot be used as a shield to prevent the disclosure to the patient of the facts of 
any adverse medical event.  
- The mandate of the Health Information and Quality Authority (HIQA) should be 
extended to the private sector.  
 30% of cancer care occurs in the private sector. 
 All cancer patients (both public and private) should have their cases 
discussed at a multidisciplinary tumour board. 
- Facilitation of data collection in screening programmes from those who decline 
participation, to allow full evaluation of the impact of these programmes.  
ii. Infrastructure 
 
- Inadequate IT infrastructure throughout the health care system, including multiple 
stand-alone Electronic Medical Records (EMRs) throughout the country is a major 
issue. 
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 The development of an EMR for cancer patients which can be shared across 
all health care providers and “mined” for cancer data should be actively 
considered. 
 The “minimum dataset” should be reviewed to ensure that all  factors 
relevant to quality of care and cancer system performance are collected (to 
ensure Safe, Effective, Accessible, Responsive, Equitable, Integrated, 
Efficient care as per Institute of Medicine)  
- Molecular diagnostic infrastructure needs to be developed as a priority to support 
advances in personalise medicine.  
- Radiation Therapy: 
 Radiation facilities in St Luke’s should be consolidated onto the St James’s 
Hospital site, as planned.  
 A capital replacement plan for current radiation equipment should be 
developed. 
- Systemic Therapy: 
 Design of chemotherapy day-care facilities should be re-evaluated with 
possible changes considered to improve pharmacy facilities, capacity, and 
patient experience. Particular attention should be given to facilitating 
assessment and management of acutely unwell patients requiring review. 
 
iii. Prevention and Screening 
 
There should be: 
- A sustained emphasis on Primary Prevention and Screening.  
- An independent evaluation of the impact of screening programmes at a national level 
to assess possible harms and benefits. 
- The development of a workforce plan for endoscopy services. 
 The roll out of the colorectal screening programme is dependent on sufficient 
numbers of endoscopists (nurses and doctors) being available.  
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iv. Organisation of Care Services 
 
The current model of service delivery needs to be re-examined and the establishment of 
“Comprehensive Multidisciplinary Oncology Teams” should be pursued. This should be 
underpinned by service specifications that embrace a major role for Clinical Nurse 
Specialists, Advanced Nurse Practitioners and Allied Health Professionals in patient 
assessment, delivery of treatment, survivorship and end-of-life care. 
 
a. Continuity of Care:  
A model of providing 24/7 care to cancer patients needs to be developed by the 
NCCP – the current default position,the panel noted, of whereby cancer patients 
with issues re-enter treatment through Emergency Departments is 
unacceptable.  
 
b. Cancer Surgery:  
 
 There seems to be  considerable delays in diagnosis and treatment due to 
lack of beds due to admissions from Emergency Departments. Some 
method of ensuring that beds for cancer patients requiring surgery are 
available is necessary. We were informed that cancellation of planned 
cancer surgery occurs on a regular basis and this should not be allowed to 
continue.  
 Continue the process of consolidation of surgical services.  
 In Gynaecological Oncology having 7 centres in a country of 4.5m 
people seems excessive.  
 Approximately 50% of lung cancer surgery is performed in one 
large centre: 
o Consider concept of Level I and Level II centres as has been 
done in other jurisdictions with Level I centres providing the 
full range of thoracic surgical care and level II centres 
providing basic thoracic surgery needs.  
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 Neurosurgery: The evaluation panel was concerned to hear that while local 
and regional referral pathways have evolved for treatment of patients with 
spinal metastases that a national or programmatic approach does not exist 
at this time– this would appear to be a potential major gap in patient care 
and should be addressed as soon as possible.  
 
c. Palliative Care: 
The planned review of Palliative Care strategies should include examination of the 
following:  
 How to integrate palliative care across the whole patient journey  
 Timing of intervention 
o Palliative Care appears, for the most part, only to be introduced to 
patients in the last few weeks of life and this is contrary to 
international best practice.   
 
d. Psycho-oncology and psychosocial support services: 
 
A comprehensive psycho-oncology and psychosocial support service plan should 
be developed as part of the next cancer strategy. 
 This should be done  in conjunction with the voluntary sector and should 
include a strategy to improve education of all health care workers in the 
psychosocial support needs of patients 
  
e. Role of Primary Care: 
 Role definition of GPs necessary to ensure a more consistent approach to 
patient management in partnership with specialist care. The evaluation panel 
noted that there was a significant disconnect between specialist care and 
primary care.  
 Access of GPs to diagnostic tests should be standardised in line with patient 
diagnostic/referral pathways. 
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f.  Patient and Family input: 
 
A strategic approach to engaging patients and families at the national and local 
level should be developed. 
 
v. Staffing Shortages: 
 
While the development of new models of care is an urgent priority, dealing with 
acute staffing shortages in all areas including nursing, allied health and physicians 
must be undertaken as soon as possible. 
- Nursing: 
 Nursing shortages in chemotherapy delivery units is a major concern 
as regards patient safety  
o Lack of Advanced Nurse Practitioners in this area was 
startling, compared to other jurisdictions 
 The widespread use of agency nurses on in-patient units (who are 
often unfamiliar with patient issues and with hospital processes) 
should be phased out 
- Allied Health Professionals: 
 Severe shortage of in allied health disciplines including pharmacists 
 Rehabilitation services poor. 
- Medical Oncology 
 Currently 34 Medical Oncologists in Ireland, international standards 
would suggest that the appropriate number of staff should be 
approximately 60 at a minimum. 
- Urology 
 There is considerable regional variation in access to prostate rapid 
access clinics due to shortage of urologists.   
vi. Oncology Nursing: 
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Nurses play a key role in all aspects of patient care along the cancer journey and 
we recommend that the NCCP and HSE appoint senior cancer nurses to all work 
streams, supported by a leadership development programme. 
vii. Hereditary Cancer Programme: 
 
A National Lead for the Hereditary Cancer Programme in the NCCP should be 
appointed and tasked with development of a National Cancer Genetics Policy as a 
matter of urgency.  This programme requires considerable expansion to meet the 
needs of patients and their families.    
 
viii. Cancer Survivorship: 
 
A national strategy for cancer survivorship needs to be developed  as part of the 
new national cancer strategy to meet the needs of the growing population of 
patients requiring follow up of their cancer and support for recovery 
 Particular attention should be given to new service delivery models 
including the contribution of GPs and primary care  
ix. Research: 
 
The promotion and facilitation of clinical and translational studies is an integral 
part of any cancer control programme. The Department of Health and NCCP 
should work with the Health Research Board and other stakeholders to: 
 Develop a comprehensive infrastructure to facilitate research  
 Establish a National Research Ethics Board for multi-institutional 
studies as has been done in other jurisdictions.  
 Review the mandate and role of the Health Research Board in 
cancer research.  
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Introduction: 
 
In 2006, the National Cancer Forum developed the Second National Cancer Plan for Ireland, A 
Strategy for Cancer Control in Ireland and over the past 7 years the recommendations of this 
strategy have guided the development of Cancer Services in Ireland. The vision of the strategy 
was that:  
“Ireland will have a system of cancer control which will reduce our cancer incidence, 
morbidity and mortality rates relative to other EU-15 countries by 2015. Irish People will 
know and practice health-promoting and cancer-preventing behaviors and will have 
increased awareness of and access to early cancer detection and screening. Ireland will 
have a network of equitably accessible state-of-the-art cancer treatment facilities and will 
become an internationally recognized location for education and research into all aspects 
of cancer.” (1) 
 
The Minister for Health, Leo Varadkar T.D., requested an external panel be drawn together 
(Professors Harry de Koning, Alison Richardson and Padraig Warde) to review and report on 
progress in cancer control since 2006.  The review was carried out with the support and help of 
the Cancer, Blood and Organ Policy Unit (Department of Health), the Office of the Chief 
Medical Officer (Department of Health), and the Health Services Executive National Cancer 
Control Programme.  
 
The terms of reference of the review panel are outlined in Appendix 1 and the areas they were 
asked to comment on included: 
 
i. evaluate the extent to which the recommendations of the strategy have been 
implemented; 
 
ii. identify deficits in the implementation of the strategy;  
 
iii. summarise success factors or barriers to success; 
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iv. identify key learning points arising from the strategy; 
 
v. assess the overall impact of the 2006 Strategy in terms of the policy indicators outlined in 
that strategy (Appendix 2); 
 
vi.   examine the projected need for cancer services over the next 10 years; 
 
vii. evaluate the level of patient input into the design of services, patient engagement in 
services and patient feedback on experiences and outcomes;   
 
viii. indicate areas for development in the next strategy; 
 
ix. comment on Ireland’s evolution in cancer control in the light of international trends, to 
include areas such as prevention, screening, system performance, KPIs, 
medical/surgical/radiation oncology, medical oncology and drug management 
programme, data capture & information systems, health intelligence, physical 
infrastructure and equipment; 
 
x.   outline the options for cancer service configuration and supporting governance 
arrangements; 
   
The review was conducted between September 29th and October 3rd 2014 in both Dublin and 
Cork with multiple meetings with senior management in the Department of Health, Health 
Services Executive, and the National Cancer Control Programme. In addition, the panel met with 
various stakeholder groups from across the country (Appendix 3) and with patients in a number 
of the institutions visited. A list of the documents supplied to the review team is given in 
Appendix 4.   
 
In this report, we have chosen not to include a detailed breakdown of the extent to which each 
recommendation of the National Cancer Strategy 2006 has been implemented, but instead we 
have taken a more holistic approach, combining review of data supplied to us and integrated this 
13 
 
with our own analysis of various issues, including comparisons with international norms as 
appropriate. We have however outlined, in a summary table, our assessment of the degree of 
success in implementing the 55 recommendations of the National Cancer Strategy 2006 
(Appendix 5). Data on 17 of the 19 cancer policy indicators from the 2006 strategy are available 
and are summarized in Appendix 6.   
 
We will initially comment on various issues that transcend the whole patient pathway e.g. IT 
infrastructure, research, multidisciplinary care delivery, workforce planning, and Quality 
Assurance etc. We will then address progress over the past 7 years in various components of the 
patient journey: Prevention, Screening, Diagnosis, Treatment, Recovery, and End-of-Life care. 
We will make recommendations for consideration in developing the next cancer strategy and, 
where appropriate, will indicate where specific changes should be considered for implementation 
as soon as possible.  
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Section A:  Issues that transcend the whole patient pathway.  
 
The evaluation panel was very impressed with the significant progress in the cancer control 
system in Ireland since the publication of “A Strategy for Cancer Control in Ireland” in 2006. 
Major improvements have been made across the whole spectrum of the patient journey from 
prevention to end-of-life care. A major achievement of the National Cancer Control Programme 
(NCCP) is that cancer services are now centralized in 8 designated Cancer Centers established in 
4 networks. This has led to major (and positive) changes in how cancer treatment is delivered 
with high volume multidisciplinary cancer services in diagnostics, surgery, radiation oncology 
and medical oncology. The various policies and strategies around Cancer Prevention developed 
during the past 7 years are excellent and these should be incorporated into the next cancer 
strategy. 
 
There has been significant progress in the area of early cancer diagnosis with the development of 
rapid access clinics, with electronic GP referral, in breast, lung and prostate and the 
implementation of three national screening programmes with excellent integration with 
diagnostic and surgical services. National referral guidelines and pathways have been developed 
in multiple cancers. Overall, in terms of achieving the vision of the National Cancer Strategy 
2006, the evaluation panel felt the NCCP has made good progress. However, there is a long way 
to go before Ireland becomes an internationally recognized location for education and research 
into all aspects of cancer.   
The major factor that contributed to success in driving change in the cancer control system was 
the leadership of the NCCP. As pointed out by the World Health Organization, proficient 
management is needed to integrate these activities into a coherent programme:  
 
“Key to competent management is the leadership of the programme, who should be 
facilitative, participatory and empowering in how vision and goals are carried out.”  (2) 
 
Overall, the evaluation panel believes that the NCCP has done a magnificent job in driving 
positive change in the cancer system. Looking to the future, we would stress that we believe that 
the NCCP should continue in its current role overseeing the Irish cancer system.  
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This will be especially important as over the next decade there will be a major growth in 
incidence of cancer and demand for cancer services (27% projected increase in incidence from 
2015 to 2025).  Also, this is important in the context of acute hospital services being reorganized 
into hospital groups. With regionalization of acute care delivery, attention is needed to ensure the 
cancer control system evolves appropriately. We believe that the cancer system would continue 
to benefit from leadership at a national level.  
 
A.1 Legislative/Structural issues:  
 
The lack of a unique patient identifier is a major issue which significantly inhibits tracking of 
patients through the public and private systems and makes care co-ordination and workforce 
capacity planning difficult. The evaluation panel feels that this should be rectified as soon as 
possible (as planned in the Health Identification Act 2014).  The National Cancer Strategy 2006 
recommended that HIQA should “Establish a National Framework for Quality in Cancer 
Control”. With the publication in 2012 of the National Standards for Safer Better Health Care 
this has largely been implemented. The NCCP has developed many strategies to assure access 
and quality of care in the public system including KPIs that are monitored on a monthly basis.  
 
However, up to 30% of cancer care occurs in the private sector and at present there is no 
assessment of the quality of care these patients receive. Implementation of National Cancer 
Strategy 2006 recommendation number 42:  
“HIQA should develop a system of licensing and accreditation of Cancer Centres and 
services that should apply to the public and private sectors; the systems of licencing 
should be given statutory effect,”  
- would largely deal with this issue provided appropriate accreditation standards are put into 
place (e.g. the need for all cancer patients to have their cases discussed at an MDT).  
 
HIQA does not have as part of its current mandate the quality of care patients receive in the 
private health care system and the evaluation panel feels that this should be reviewed as part of 
the next cancer strategy. This framework needs to embrace all the dimensions of quality as 
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outlined by the Institute of Medicine in its landmark report on Quality (and contained in the 
National Standards for Safer Better Healthcare in Ireland 2012): Safety, Efficiency, Patient 
Centredness, Effectiveness, Equity and Timeliness (3,4). This licensing and accreditation 
framework should also be applied within the publicly funded cancer system. 
 
The National Cancer Registry of Ireland (NCRI) collects data on cancer cases in Ireland and 
provides some analysis on treatment outcomes. The National Cancer Strategy 2006 (rec. 44) 
recommended that “Mandatory notification of cancer should be put in place through 
appropriate legislation” This has not been done and the review panel feels that this should be 
implemented and that this change, along with the introduction of a unique patient identifier, 
would allow the Department of Health to work more closely with NCCP to monitor progress in 
improvements in delivery of care and patient outcomes (e.g. development of new Quality 
Indicators such as adherence to treatment guidelines).  
 
Public reporting on quality of care and performance is an essential aspect of a high-performing 
cancer system and while the NCCP currently does an excellent job on reporting various key 
performance indices on a regular basis, the evaluation panel feels that continuous quality 
improvement is another hallmark of a high-functioning health care system. To promote the 
sharing of information and open discussions among health professionals, (which can lead to 
improved patient care and safety) consideration should be given to legislative protection from 
disclosure in legal proceedings for information provided to hospital quality of care committees 
(and other designated quality of care committees) that deal with quality improvement. This 
legislative protection should be designed to encourage health professionals to share information 
and hold open discussions to improve patient care, without fear that the information will be used 
against them. Under such legislation, information that deals with quality improvement would be 
shielded from disclosure in legal proceedings. However, the legal protections for quality of care 
information should be designed so that it cannot be used as a shield to prevent the disclosure to 
the patient of the facts of any adverse medical event. More openness about errors would help 
devise potential solutions to ensure they do not recur and is a key component of the patient safety 
agenda in other jurisdictions (5). 
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A.2 Information Technology Infra-structure issues: 
 
The National Cancer Strategy 2006 (rec. 48) recommended that: 
“Information systems and information technology should be developed by the HSE to 
support the management and delivery of cancer services”.  
Suboptimal IT infrastructure throughout the health care system, including multiple stand-alone 
Electronic Medical Records (EMRs) throughout the country was a recurrent theme in many of 
our meetings. This, along with lack of a unique patient identifier, results in poor communication 
between care providers, lack of appropriate data for planning and coordinating services, 
difficulties with monitoring performance using KPIs, and makes clinical and translational 
research difficult on a national level. There has been considerable progress in this area, 
especially with electronic referrals from GPs to designated cancer centres. However, data 
collection for many hospitals remains a challenge. The development of an EMR for cancer 
patients, underpinned by a unique patient identifier, which can be shared across all health care 
providers and “mined” for cancer data, should be actively considered. A key area currently under 
review is a national medical oncology IT system for the prescription and safe administration of 
chemotherapy. While this is very important, the evaluation group would suggest that the 
development of multiple “stand-alone” systems could lead to unnecessary fragmentation and that 
the purchase or development of one system that links all treatment disciplines be considered.   
 
The “minimum dataset” for collection on each cancer patient should be reviewed to ensure that 
all factors relevant to Quality of Care and Cancer System Performance are collected (to ensure 
Safe, Effective, Accessible, Responsive, Equitable, Integrated, Efficient care as per Institute of 
Medicine).   
A.3 Models of Care/Workforce planning 
 
We believe there are considerable opportunities for deployment of new models of care. In 
particular, the establishment of “Comprehensive Multidisciplinary Oncology Teams” 
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underpinned by service specifications that embrace a major and increased role for clinical nurse 
specialists, Advanced Nurse Practitioners and allied health professionals in patient assessment, 
delivery of treatment, survivorship and end-of-life care should be pursued. Similarly, there are 
opportunities for moving to different delivery models (which can often result in a higher quality 
of care) along the whole continuum of the patient journey. This will become increasing 
important in the future as the population ages and there is increasing need to contain health care 
costs.  Along with this, manpower needs for the future should be examined for all medical, 
nursing and allied health specialties as suggested by the National Cancer Strategy 2006 (rec. 48): 
“The HSE should develop a national cancer workforce plan to fully implement national cancer 
policy”.  
A.4 Oncology Nursing  
 
Nurses play a key role in all aspects of patient care along the cancer journey. The review panel 
was very impressed with the Strategy and Educational Framework for Nurses Caring for 
Patients in Ireland document and progress with implementation to date. This has been achieved 
in large part by a small group of committed individuals, and despite the absence of investment in 
specialist cancer nursing leadership at a local and national level. The panel believes that action 
should be taken  to strengthen the  leadership of specialist cancer nursing within the context of 
the NCCP through the nomination of named individuals to all relevant workgroups.  Moving 
forward consideration needs to be given to more fully utilising the scope of practice of oncology 
nurses in the delivery of services. 
 
 
A.5  Quality Assurance 
 
Quality assurance programmes are a key cornerstone of all Cancer Control programmes. The 
evaluation panel was very impressed by the progress to date of the National Quality Assurance 
Programmes (developed by the Royal College of Physicians of Ireland and the Royal College of 
Surgeons in Ireland with the support of the NCCP) in Histopathology, Endoscopy and 
Radiology. These programmes are focused on the work of clinicians and are building a culture of 
quality in these fields, and are crucial for evaluation of screening programmes.   
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A.6  Research 
 
The  promotion of research is an important part of any Cancer Control programme. ICORG, the 
Ireland Clinical Oncology Group has been successful in making oncology clinical trials available 
to Irish patients. ICORG is funded by grants primarily from the Health Research Board, with 
some support from the Irish Cancer Society, and accrues patients to studies in the Republic of 
Ireland, whilst also being open to patients in Northern Ireland. The panel was impressed with the 
breadth of studies available to patients and with accrual to trials. (6) However, the lack of a 
comprehensive infrastructure to facilitate research was commented on by many groups and what 
is there, appears not to be co-ordinated to best effect. Establishment of a national Research 
Ethics Board for multi-institutional studies, as has been done in other jurisdictions, would be 
very helpful. (7) The Health Research Board is an autonomous statutory agency whose mandate 
is to promote health care research in Ireland. It is funded by a grant from the Department of 
Health (around €30m per annum) and approximately 25% of their grants go to promote cancer 
research. The review panel examined the grants approved by the HRB and in our discussion with 
staff we were unable to discern a clear strategic vision as to what the HRB wished to achieve in 
the cancer domain. We would suggest a multidisciplinary research agenda that spans the 
spectrum of basic laboratory to clinically relevant research to population level research  (bench 
to bedside) should be promoted by the HRB.  
 
 A.7  The Patient Voice 
 
We believe that patient input, engagement, and feedback has not received the attention it 
deserves from all parties involved in national cancer strategy implementation and that there is a 
lack of a strategic approach to engaging patients and families at the national and local level. 
Activities, where they occurred, have been largely consultative or focussed on review of patient 
information materials and ad-hoc patient satisfaction surveys, rather than involving them in co-
producing patient centred services. We believe that this is a serious gap and must be addressed if 
the NCCP is to be assured that the cancer programme is responsive to the needs of patients and 
families. There is extensive experience in other jurisdictions as to appropriate ways to engage 
families and patients in all aspects of the cancer systems. (8) 
20 
 
A.8 Public reporting 
 
Public reporting on quality of care and performance is an essential aspect of a high-performing 
cancer system. Whilst the NCCP currently does an excellent job on reporting various key 
performance indices on a regular basis, the evaluation panel feels that a cancer system quality 
reporting system based on the various components of Quality of Care as described by the U.S. 
Institute of Medicine and the National Standards for Safer Better Healthcare, should be 
developed by the NCCP. This is similar to what is done in other jurisdictions and provides a 
regular public assessment of the quality of care and performance in the cancer system. (9) 
 
  Recommendations: 
 
For Implementation as soon as possible: 
 
1. Implementation of a national unique patient identifier as planned in the Health 
Identification Act 2014. 
2. Mandatory notification of cancer diagnosis should be put in place through appropriate 
legislation as recommended in the National Cancer Strategy 2006. 
3. Extension of the mandate of HIQA to monitor the quality of care patients receive in 
the private health care system. 
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For Consideration going forward:  
 
1. The current model of delivery of services should be re-examined, with particular 
attention given to the development of “Comprehensive multi-disciplinary oncology 
teams” with clear delineation of responsibility and authority for individuals in these 
teams. This should be underpinned by an integrated workforce strategy.  We strongly 
recommend that the NCCP and HSEvappoint senior cancer nurses to all workstreams 
supported by a leadership development programme. 
2. The IT infrastructure issue needs to be addressed in a comprehensive fashion. In 
particular, the evaluation panel would suggest that the development of an Electronic 
Patient Record be considered as a matter of some urgency.  
3. Clinical and translational research support should be considered a core function in the 
next National Cancer Strategy 
4. The mandate and role of the Health Research Board in cancer research funding  
should be reviewed 
5. Establishment of a national research ethics board for multi- institutional studies.  
6. Expansion of the role of the NCRI to report on (with HIQA and the NCCP) progress 
in improving cancer control.  
7. Patient and public involvement in strategy formulation, service development and 
evaluation should be integral to the next national cancer strategy.  All providers of 
cancer services should develop and implement a strategy to ensure patients and 
families are involved in the development and evaluation of services with a focus 
improving outcomes and experiences of most importance to them.  An overarching 
framework is needed to underpin evaluation of patient outcomes and experience in a 
comprehensive manner. 
8. Legislative protection from disclosure in legal proceedings for information provided 
to hospital quality of care committees (and other designated quality of care 
committees) that deal with quality improvement should be considered. This 
legislative protection should be designed to encourage health professionals to share 
information and hold open discussions to improve patient care, without fear that the 
information will be used against them. 
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9. Development by the NCCP of a publicly reported cancer system quality reporting 
system based on the various components of Quality of Care as described by the U.S. 
Institute of Medicine.  
Section B:  Issues along the patient pathway 
 
B.1 Cancer Prevention 
 
The National Cancer Strategy 2006 made 12 recommendations for Health Promotion and there 
has been excellent progress in this area by the Department of Health in conjunction with the 
HSE, including the development of national disease specific policies and strategies as outlined in 
Appendix 3 of the Report on the Implementation of A Strategy for Cancer Control in Ireland 
2006 (September 2014) produced by the NCCP (10). These include an increased focus on 
obesity prevention, stopping smoking, decrease in alcohol ingestion, and the need to promote 
physical activity as outlined in Healthy Ireland. (11) In particular the National Cancer Strategy 
2006 (rec. 3-5) made 3 specific recommendations aimed at reducing smoking prevalence in 
Ireland including 
- Compliance with all provisions of the Public Health (Tobacco) acts, 2002 and 2004 
should be monitored. 
- Excise Duty on cigarettes should be substantially increased each year above the rate 
of inflation. 
-  Nicotine replacement therapy should be made available free of charge to all medical 
card holders. 
These recommendations have largely been implemented and have been remarkably successful in 
reducing smoking prevalence. In 2007 approximately 29% of the population smoked and this has 
dropped to 24% in 2010 and 22% in 2012, which is in accordance with international standards.  
As regards alcohol misuse the National Substance Misuse Strategy of 2012 identified a number 
of concrete measures that have been incorporated into the proposed Public Health (Alcohol) Bill. 
These include: 
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- Minimum unit pricing for alcohol products 
- The regulation of advertising and marketing of alcohol 
- Structural separation of alcohol from other products in mixed trading outlets  
- Health labelling of alcohol products 
- Regulation of sports sponsorship.  
If these alcohol misuse measures are introduced in Ireland, it will become an international leader 
in the field.  
 
There has been substantial progress in all the other health promotion recommendations of the 
National Cancer Strategy 2006 including implementation of the National Task Force on Obesity 
recommendations, promotion of safe sun practices, radon measurements, and in particular 
monitoring of the inequalities in cancer risks, cancer occurrence, cancer services and cancer 
outcomes by the National Cancer Registry of Ireland. 
 
The Evaluation Panel feels overall there has been excellent progress in the area of Prevention 
over the past 7 years and that the recommendations of the National Cancer Strategy 2006 have 
largely been implemented. 
 
Recommendations: 
 
1. The various policies and strategies developed in the past 7 years are excellent and should 
be incorporated into the next cancer strategy.  
2. The fact that cancer prevention is everyone’s business should be emphasised in the next 
strategy – in particular we would recommend that a strategy be developed to incorporate 
education on prevention into all aspects of the Cancer Control Programme e.g. use 
Screening Programmes, Treatment Programmes, venues and staff to promote healthy 
lifestyle behaviour. Smoking cessation programmes should be promoted and readily 
available within all health care facilities and especially within Cancer Centres. The 
promotion of healthy life style behaviours should be a central component of the cancer 
survivorship strategy moving forward. As the cancer workforce are a key enabler in that 
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they support and influence patients, a framework to support practice change in health 
professionals should be developed. 
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B.2 Screening 
 
The National Cancer Strategy 2006 made 8 recommendations for screening/early detection and 
there has been very good progress in this area including the development of the National 
Screening Service which currently delivers 4 national programmes, BreastCheck, CervicalCheck, 
BowelScreen, and the Diabetic RetinaScreen.    
Breast cancer screening is currently offered to women aged 50-64 and since 2007 two rounds of 
national screening have been completed. In total, nearly 450,000 women have been screened and 
there has been a consistently high rate of uptake of invited women (71%). The BreastCheck 
location toured by the group (Eccles Street) was very well designed and the evaluation panel 
noted with approval that digital mammography is exclusively used. The evaluation panel also 
noted that if cancer is diagnosed, that there appears to be excellent integration with surgical 
services.   
Extension of the upper screening age to 69 was announced by the Irish Government in October 
2014. This age extension fulfils one of the key screening recommendations of the National 
Cancer Strategy 2006 and brings Ireland in line with both  EU and international guidelines in 
breast cancer screening.  The evaluation panel was impressed with the quality assurance and 
audit programme of BreastCheck and in particular the voluntary accreditation with the European 
Reference Organisation for Quality Assured in Breast Screening and Diagnostic Services 
(EUREF).  
Cervical cancer screening is currently offered to women aged 25-60 and since 2007 two rounds 
of national screening have been completed with excellent uptake, 83% for women aged < 30 and 
74% overall. Access to Colposcopy services is monitored and has improved significantly.  The 
national roll-out of this programme fulfils another key screening recommendation of the 
National Cancer Strategy 2006. The evaluation panel was impressed with  the plans of 
CervicalCheck to perform a formal Health Technology Assessment  on possible changes 
required to  the screening strategy going forward with the change in population being screened 
(after incorporation of HPV vaccination), and the evolving role of primary HPV testing for 
cervical cancer. The panel also noted the high level of satisfaction by the women screened and 
that > 99% would recommend using the service to a family member or friend. (12) 
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Bowel Cancer screening is being introduced in a phased way between 2013 and 2015 starting 
with men and women aged 60-69. There is a plan is to extend the age to between 55-74 in the 
future, in line with international recommendations. The evaluation panel noted that it is the first 
national screening programmes to use the fecal immunochemical test (FIT) test. The programme 
appears to be well integrated with accredited colonoscopy services and surgery for cancer 
patients. Going forward it will be essential to ensure that there are sufficient endoscopists, which 
can be either nurses or doctors, to deal with the demand as the screening age is extended.  The 
national roll-out of this programme fulfils another key screening recommendation of the 
National Cancer Strategy 2006.  
Independent evaluation of the impact of screenming programmes at a national level to assess 
possible harms and benefits should be performed on a regular basis. This would be facilitated by 
a regulatory/legislative change to allow for data collection from those who decline participation 
in screening programmes.   
The Evaluation panel feels overall there has been excellent progress in the area of Screening over 
the past 7 years and that the recommendations of the National Cancer Strategy 2006 have largely 
been implemented. 
 
Recommendations: 
 
1. The approved age extension for those aged 65 – 69 inclusive, to be rolled out in the 
BreastCheck programme, should be completed and appropriately resourced as soon as 
possible.  
2. Likewise, rapid extension in the BowelScreen Programme is essential.  
3. Extension of screening programmes to high-risk populations should be considered. This 
is particularly relevant in breast cancer screening and should be linked to the hereditary 
cancer programme.  
4. The opportunity for the National Screening Service to be involved in promoting cancer 
prevention strategies should be explored.  
5.  Independent evaluation of the impact of screening programmes at a national level to 
assess possible harms and benefits should be performed on a regular basis and there 
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should be  a regulatory/legislative change to allow for data collection from those who 
decline participation in screening programmes 
 
B.4 Diagnosis 
 
An important recommendation of the National Cancer Strategy 2006 (rec. 20) was that “The 
HSE should develop specific programmes that promote early detection of cancer.” There has 
been definite progress in this area with the development of rapid access clinics in breast, lung 
and prostate. Electronic patient referral to these clinics appears to be working well. National 
referral guidelines for GPs have been developed in Breast Cancer, Lung Cancer, Prostate Cancer 
and Melanoma and are being finalised in Ovarian Cancer and Head & Neck Cancer. Referral 
pathway documents for GPs have also been developed in Breast Cancer, Lung Cancer and 
Prostate Cancer, and a pathway for Ovarian Cancer is in development. However, while these 
pathway and guideline documents appear to be excellent and appropriate the evaluation panel 
found significant problems with the implementation of these services: 
- Access to diagnostic services appears to be a major problem for some General 
Practitioners. It was pointed out to the panel there are often considerable delays in 
obtaining appropriate diagnostic tests and outpatient appointments for symptomatic 
patients. In addition, there appears to be considerable regional variation in access to 
laboratory and imaging services. In discussions with representatives of the Irish 
College of General Practitioners we were informed that 20% of GPs have no access to 
diagnostic ultrasound. This is concerning given the fact that that the “Ovarian Cancer 
GP Referral Pathway” document produced by the NCCP Community Oncology 
Programme specifically recommends “urgent ultrasound of the Abdomen and Pelvis” 
in certain cases. 
- Communication with GPs from the rapid access clinics and hospital services in 
general needs to be improved.  
- In discussion with patients the lack of “Equity” in this area was mentioned. Some 
patients we talked to had quite different experiences with diagnosis – those who could 
afford to access the Private System for imaging tests and biopsy were apparently 
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diagnosed in a more timely fashion than those who had to rely on services in the 
Public System .   
- GPs and patients made the point on a number of occasions that while they were in 
general satisfied with the “Cancer Programme” when they “managed” to access the 
“Cancer System”, that securing a diagnosis in a timely manner was often very 
frustrating and associated with considerable delays and anxiety.  
- There appears to be considerable regional variation in timely access for prostate 
cancer diagnosis with the South-East of the country having especially poor service.  
- The fact that the Breast rapid access clinics are being stretched by non-urgent patients 
who likely do not need specialised evaluation was pointed out to the panel on a 
number of occasions (the term “over-whelmed” was used by a number of physicians).   
Another important recommendation of the National Cancer Strategy 2006 (rec. 34) was that “A 
National Cancer Genetics Policy should be developed”. While the National Center for Medical 
Genetics in Crumlin does some work in this area the panel heard from many sources that the 
nascent National Hereditary Cancer Programme is poorly resourced and developed, and requires 
considerable expansion to meet the needs of patients and their families.    
 
The Evaluation Panel feels overall there has been definite progress in the area of Diagnosis over 
the past 7 years, and that the recommendations of the National Cancer Strategy 2006 have 
largely been implemented, with the exception of the recommendation on the development of a 
National Cancer Genetics Policy. 
 
Recommendations: 
For Implementation as soon as possible: 
 
1. The issue of consistent timely access to appropriate diagnostic tests for GPs and hospital 
appointments for symptomatic patient’s needs to be addressed as a matter of urgency.  
2. Refine referral pathways and service models  to ensure specialist oncology referral is 
reserved for those who need it and to avoid the worried well overloading specialist cancer 
clinics.  This should be accompanied by public education programmes. 
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3. Disparities in access to diagnostic ultrasound and other tests should be addressed. 
4. Variation in access to rapid diagnosis clinics should not be allowed to continue – the 
panel believes that this likely will involve recruitment of additional specialists in some 
communities. 
5. A National Lead for the Hereditary Cancer Programme should be appointed by the NCCP 
and tasked with development of a National Cancer Genetics Policy as a matter of 
urgency.    
 
For Consideration going forward:     
   
1. Extension of the rapid access clinic model to other cancers. 
2. Development of further National Referral Guidelines and Pathways for GPs 
3. Investment in educational strategies for GPs in these Guidelines and Pathways 
 
B.5 Treatment 
 
The National Cancer Strategy 2006 made numerous recommendations on how cancer care 
should be delivered. Specifically it recommended that “All Cancer Care should be delivered 
through a national system of four managed Cancer Control Networks, each serving a population 
of approximately one million people”. A major achievement of the NCCP is that cancer services 
are now centralised in 8 designated Cancer Centres established in 4 networks (with Letterkenny 
Hospital acting as a satellite of University College Galway for Breast Cancer surgery). This has 
led to major (and positive) changes in how cancer services are delivered in Ireland. Prior to the 
development of the National Cancer Strategy 2006 cancer treatment was fragmented with many 
patients treated in small centres with low volumes and little access to multidisciplinary 
consultation.  
The key aspects of the designated cancer centres are sustainable high volume multidisciplinary 
cancer services spanning the range of diagnostics, surgery, medical oncology and access to 
radiation oncology. All new patients and selected patients with complex recurrent disease are 
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reviewed in multidisciplinary team meetings comprising all diagnostic and therapeutic 
specialists.  
It was recommended in the National Cancer Strategy 2006 (rec 32) that:  
“The HSE should conduct a review of the number of centres required for management of 
symptomatic breast disease to bring them into line with designated cancer centres.”  
Breast cancer surgery has now been centralised from 32 hospitals to 8 cancer centres. The NCCP 
has moved to centralise services into designated cancer centres in prostate, lung, pancreas, rectal 
and oesophageal cancers. This is work in progress with for example 77% of rectal cancer 
surgeries currently being performed in cancer centres. While improvements in 5-year survival 
are expected these will not be evident until there is 5-year follow-up after implementation of 
these changes.  
National Tumour Groups have been developed by the NCCP, in collaboration with the Royal 
College of Physicians of Ireland and the Royal College of Surgeons in Ireland. These have 
produced comprehensive, succinct and evidence based guidelines for the management of many 
clinical conditions and these are now being introduced into practice. In the future, these will 
facilitate the introduction of an important quality metric – adherence to guidelines in the 
treatment of patients.  
 
Overall, the evaluation panel was very impressed with the excellent progress in the treatment of 
cancer patients by the NCCP over the past 7 years. However, we heard from stakeholder groups 
(and especially from patients) regarding many problematic areas in the treatment domain. We 
recognise that many of these problems arose because of the fiscal crisis in the country but feel 
that they need to be highlighted so that they can be addressed. The specific problems included: 
- HR issues:  
Inadequate staffing was a major theme throughout virtually all meetings with staff 
and patients throughout the country. We heard descriptions of a fragmented cancer 
delivery system, a system in crisis, held together by goodwill. Morale appears to be 
very poor in certain professional groups. It would appear that insufficient attention is 
being paid to developing alternative models of care such as moving care delivery to 
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less expensive models e.g. integration of advance practice nurses in Oncology Teams, 
thereby reducing the need for additional Consultant Physicians. It was pointed out to 
the evaluation panel that it is difficult to plan for the future when the prevailing 
feeling among many health care workers is that the system is in crisis. We highlight 
here some of the major issues but staff shortages leading to gaps in care delivery are 
evident throughout the Cancer Programme.  
o Nursing: The Employment Control Framework has had a major detrimental 
effect in the cancer programme. We heard repeatedly, including on a number 
of occasions from patients, that staff are overworked, demoralised and cannot 
deliver appropriate care. Patients told us that that they do not feel safe at night 
in hospital, largely because of the widespread use of agency nurses who are 
often unfamiliar with patient issues and with hospital processes. Nursing 
shortages in chemotherapy delivery units is another major concern as regards 
safe delivery of treatment. The lack of Advanced Nurse Practitioners 
throughout the programme was startling compared to other jurisdictions.   
o Allied Health: There is a severe shortage of allied health professionals in the 
Cancer Programme and there would appear to be no comprehensive strategy 
to ensure patients have access to appropriate rehabilitation facilities to better 
enable them to recover after treatment and in some cases actually continue 
with treatment (e.g. Social Worker support, Speech Therapist for swallowing 
difficulties). The shortage of pharmacists is another concern and while 
excellent work has been done by the NCCP in developing an Oncology 
Medication Safety Review Report, the shortage of pharmacists gives rise to 
patient safety concerns.  
o Administrative staff: Again here, the Employment Control Framework has 
had a major detrimental effect in the cancer programme. One specific example 
the evaluation group found hard to believe was that apparently a National 
Neuro-Oncology Lead was recruited without appropriate administrative 
support.  
 Neuro-Oncology; The National Neuro-Oncology Programme is based in 
one centre in Dublin with a satellite unit in Cork.  This would appear to be. 
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an appropriate organisational model. However, the committee was 
concerned to hear that, while local and regional referral pathways have 
evolved for treatment of patients with spinal metatastases, that a national 
or programmatic approach does not exist at this time– this would appear to 
be a potential major gap in patient care and should be addressed as soon as 
possible.  
o Medical Oncology: There are currently 34 Medical Oncology posts in Ireland 
of which 31 are filled by permanent staff. International standards would 
suggest that the appropriate number of staff should be approximately 60 at a 
minimum (4). The situation is especially acute in the Cork and Kerry area, 
where for a catchment area of nearly 800,000 people there are only 2 fulltime 
Medical oncologists in practice, helped by 1 locum physician. In addition, 
there would appear to be no Advanced Nurse Practitioners who can make a 
significant contribution to the management of chemotherapy patients. An 
additional problem appears to be that Non-Consultant Hospital Doctor support 
in Medical Oncology is poor, likely due to difficulty filling training posts as 
these are not seen to be attractive due to excessive workload. 
                                       
- Palliative Care:  
The National Cancer Strategy 2006 (rec. 35) recommended that:  
“The HSE should ensure that each Managed Cancer Centre Control Network 
has a comprehensive specialist palliative care service.”  
In contrast to the well-designed Palliative Care Centre we visited, we heard 
repeatedly that the palliative care services available to patients are not integrated with 
mainstream cancer care for a whole variety of reasons including lack of specialist 
palliative medical and nursing teams. In addition, we heard that there is some 
resistance from cancer specialists to the contribution palliative care can make to 
patient management.  
 
Palliative Care often appeared only to be introduced to patients in the last few weeks 
of life and this is contrary to international best practice.  There is a need to transform 
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the model of care and ensure actions are taken to achieve an effective interface 
between palliative care and cancer care, especially in acute hospitals (perhaps by 
involving palliative care teams in MDTs and establishing joint clinics) and to link 
services to primary care. This will require attention to organisational and structural 
aspects of care delivery, such as the integration of specialists in palliative medicine 
within the comprehensive multidisciplinary oncology teams (and other work to ensure 
the standardisation of and access to palliative care for all cancer patients).In addition, 
attention should be paid to fostering a culture which values the role of palliative care 
alongside the delivery of cancer treatment.  
 
We would however point out that there are some areas in which there is excellent 
Palliative Care Delivery, but this tends to be confined to the hospice context as 
opposed to enabling patients and their families to access specialist palliative care 
early in their disease trajectory. Education of non-specialist palliative care providers 
in the skills, knowledge and attitudes necessary to provide good palliative is 
important. This can be achieved in a number of ways including ensuring palliative 
care training is incorporated into the curriculum for trainees in all disciplines.   
 
- Psychosocial Care:  
The National Cancer Strategy 2006 (rec. 37) recommended that:  
“The HSE should ensure that access to comprehensive psycho-oncology and 
psychosocial support is provided for cancer patients and their families in each 
Managed Cancer Control Network”.  
This recommendation has not been implemented in any meaningful way and we heard 
repeatedly that this aspect of cancer care is poorly organised and delivered in the 
Cancer Programme. The various cancer charities appear to provide excellent support 
in this area, where they can, but there would appear to be no service delivery plan for 
psycho-oncology and psychosocial support for cancer patients in the country. There 
was a perception amongst patients and families of inadequate support being available 
in the voluntary sector.  In addition, there would appear to be a need to train cancer 
health care professionals in the psycho-social issues that cancer patients face and how 
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to manage communication about diagnosis and prognosis sensitively – we heard on a 
number of occasions from patients that, while most staff were caring and 
professional, that some were dismissive and added to patients difficulties in coming 
to terms with their illness.  
 
- Surgical Services: While there has been great success in centralising surgical services 
in the past 7 years the evaluation panel heard that there are some opportunities to 
continue this process. Specifically, in Gynae Oncology it would seem that having 7 
centres in a country of 4.5m people would seem excessive. In addition, approximately 
50% of lung cancer surgery is performed in one large centre and there may well be an 
opportunity for consolidation of services in this area as well, perhaps by considering 
the concept of Level I and Level II centres as has been done in other jurisdictions. 
Level I centres would be tertiary care facilities equipped to manage the full range of 
thoracic surgical care and Level II or secondary care units would provide basic 
thoracic surgical needs.  (13)  
 
While both medical and radiation oncology services are delivered in an ambulatory 
care setting surgical care is mainly delivered on an in-patient basis. Patients 
frequently have their surgery delayed because of lack of beds – due to admissions 
from the Emergency Department. This often leads to considerable delays in diagnosis 
and treatment and is a major source of frustration for both patients and medical staff. 
Surgery is by far the most important curative treatment strategy for cancer and some 
method of ensuring that beds for cancer patients requiring surgery are available when 
required. Frequent cancellation of planned cancer surgery should not occur.  
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- Lack of facilities to assess cancer patients requiring urgent care while on active 
treatment.  
The lack of access to cancer care “after hours” was a major theme in our discussion 
with patients. Many of them told us that they would “in no circumstances” go to the 
Emergency Department for care unless they absolutely had to because of long waits 
to be seen, lack of access of medical staff to their records and lack of understanding 
of the care they required. Even when they were admitted to hospital via Emergency 
Departments there appeared to be a lack of continuity of care in certain circumstances 
from the Oncology Team. One patient recounted that during one admission for a chest 
infection while on chemotherapy he was moved on 16 different occasions around the 
hospital and had limited contact with his oncology team. This problem is not confined 
to chemotherapy patients as patients with complications after surgery also appear to 
suffer from a similar lack of continuity of care.  
Chemotherapy day-care facilities:  Most chemotherapy day-care centres were not 
designed for this purpose and demand for chemotherapy is outstripping capacity.  This 
has led to significant difficulties in the delivery of modern state-of-the-art care including 
integration of pharmacists into the delivery team, patient privacy and comfort, and 
inability to segregate immune-compromised patients.  The lack of facilities to assess 
patients with urgent care needs when they arrive for their chemotherapy appointment (as 
noted above) was a recurring theme.  
Radiation Facilities: The National Cancer Strategy 2006 (rec. 40) recommended that 
“The National Network for Radiation Oncology Services should be established by the 
HSE in accordance with the timelines set by Government. Since 2007 there has been 
great progress in this area and two new facilities have opened in Dublin and expanded 
facilities are being built in Cork and Galway. The evaluation panel heard on a number of 
occasions that additional capacity, if needed, could possibly be purchased from the 
private sector.  The committee does not recommend this approach as the provision of 
Radiation Medicine services is not simply reliant on procuring fractions of radiotherapy 
but rather relies on a complex multidisciplinary team approach to patient care. The 
average life span of linear accelerators is approximately 10-12 years and while many of 
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the treatment units currently in use are quite new, a machine replacement plan should be 
developed as part of the next cancer strategy.  
 
Recommendations: 
 
For Implementation as soon as possible: 
 
1. Appointment of permanent staff rather than reliance on agency nursing staff, and 
locums. This is especially important in in-patient and chemotherapy day care 
units.     
2. Review of the National Neuro-Oncology services, with a special emphasis on the 
role of neurosurgery in the management of spinal metastases.  
3. Review of Medical Oncology staffing needs with a particular emphasis on 
staffing in areas outside Dublin. 
4. Review of how to ensure that treatment delays are minimised for patients who 
require surgery for cancer control.  
 
 For Consideration going forward:     
 
1. The National Palliative Care Strategy should be re-examined with particular attention 
as to how to integrate palliative care across the whole patient journey. 
2. A comprehensive psycho-oncology and psychosocial support service plan should be 
developed in conjunction with the voluntary sector. This should include: 
a. A strategy to improve education of all health care workers in the psychosocial 
support needs of patients. 
b.  The introduction of a standardised approach to assessment of psychosocial 
distress. 
3. Consideration should be given to increased consolidation of surgical services. 
37 
 
4. Models of providing 24/7 care to cancer patients should be explored – outside of the 
default position of sending them to Emergency Departments.  
5. Chemotherapy day-care facilities should be re-evaluated with possible design changes 
considered to improve patient capacity and flow among other issues.   
6. A replacement plan for radiation therapy equipment should be implemented in line 
with target dates. 
 
B.6  Recovery 
 
Planning for cancer survivorship appears to have received little attention over the past 7 years 
and was not specifically addressed in National Cancer Strategy 2006. The Community Oncology 
division of the NCCP presented an outline of a three year plan with an emphasis on the 
development of a treatment summary and care plan for patients as they transition out of acute 
cancer care. This plan includes promotion of self-management by patients, training and 
education and research. Until recently  there has only been a modest amount of  effort applied to 
thinking  about how service delivery models might need to evolve (including the contribution of 
GPs and primary care) to meet the needs of the growing population of patients requiring follow 
up of their cancer and support for recovery.  The impact of cancer and cancer treatment on the 
health and quality of life of cancer survivors is substantial and advances in early detection, 
effective therapies and supportive care has led to burgeoning numbers of cancer survivors in 
many developed countries. 
The last decade has ushered in a new era in the United States, Canada, Australia and Europe, 
heralded by an interest in health, functioning and psychosocial well-being of those living with 
and beyond a cancer diagnosis. This has naturally led to questions about the most appropriate 
configuration of services and models of care for follow up care. It is recognised that many 
survivors have ongoing needs and they may encounter fragmented, poorly co-ordinated follow 
up care.  It is now widely accepted that this demands comprehensive management namely: 
prevention and surveillance for recurrent and new cancers as well as psychosocial late effects; 
intervention for the physical and psychosocial consequences of cancer and its treatment; and 
coordination between specialists and primary care providers (14,15). Many jurisdictions are 
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developing evidence-based models to address the needs of cancer survivors that are underpinned 
by a philosophy centred on recovery, health and well-being and include programmes designed to 
better enable people to manage self-care requirements in the period of cancer survivorship 
following treatment completion. This will be an important area going forward, currently Ireland 
has > 100,000 long term survivors from cancer and this will grow considerably over the next 
decade. Attention also needs to be given to those living with advanced cancer, alongside those 
who have received curative treatment. 
 
 
Recommendation: 
 
1. A National Plan for cancer survivorship should be an integral component of the next 
cancer strategy.  
 
B.7  End-of-Life Care 
 
This has already been discussed in the treatment section above. However, it should be 
emphasised again that Palliative Care and Symptom Management services should be integrated 
across the whole continuum of cancer care.  The strategy going forward should address by 
consensus service models to underpin the delivery of exemplary end of life care and 
consideration given to the development of service specifications for specialist palliative care. 
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Glossary 
NCCP – National Cancer Control Programme 
ICORG All Ireland Cooperative Oncology Clinical Research Group 
HIQA - Health Information and Quality Authority 
ED – Emergency Department 
HRB Health Research Board 
HSE Health Services Executive 
MDT Multidisciplinary Tumour Board 
NCRI National Cancer Registry Ireland 
EMR Electronic Medical Record 
EUREF European Reference Organisation for Quality Assured Breast 
Screening and Diagnostic Services  
FIT Fecal Immunochemical Test 
HPV Human Papillomavirus 
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Appendix 1 
 
Evaluation of the National Cancer Strategy 2006 (A Strategy for Cancer 
Control in Ireland ) 
1. Scope of Evaluation 
 
The evaluation of the 2006 strategy will include consideration of the outcomes of the 
recommendations therein and indicate the overall impact of the strategy on cancer control. The 
evaluation will also review where Ireland is located in terms of developments internationally and 
will make recommendations for the future. The evaluation will also assess current practice in 
cancer control against the policy indicators outlined in A Strategy for Cancer Control in Ireland. 
 
2. Monitoring Structures 
An Advisory Group comprising representatives of the Cancer, Blood & Organs Policy Unit, the 
Office of the Chief Medical Officer (Department of Health) and the HSE National Cancer 
Control Programme (Appendix I) has been established and it will support and facilitate the work 
of the Evaluation Group.   
 
An Oversight Group (Appendix II) has been put in place to oversee the work of the Evaluation 
Group.  
3. Terms of Reference of Evaluation Group 
 
The terms of reference of the Evaluation Group will be as follows: 
 
xi. evaluate the extent to which the recommendations of the strategy have been 
implemented; 
 
xii. identify deficits in the implementation of the strategy;  
 
xiii. summarise success factors or barriers to success; 
 
xiv. identify key learning points arising from the strategy; 
 
xv. assess the overall impact of the 2006 Strategy in terms of the policy indicators outlined in 
that strategy (Appendix III); 
 
xvi.   examine the projected need for cancer services over the next 10 years; 
 
xvii. engage in appropriate consultation with stakeholders; 
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xviii. evaluate the level of patient input into the design of services, patient engagement in 
services and patient feedback on experiences and outcomes;   
 
xix. indicate areas for development in the next strategy; 
 
xx. comment on Ireland’s evolution in cancer control in the light of international trends, to 
include areas such as prevention, screening, system performance, KPIs, 
medical/surgical/radiation oncology, medical oncology and drug management 
programme, data capture & information systems, health intelligence, physical 
infrastructure and equipment; 
 
xxi.   outline the options for cancer service configuration and supporting governance 
arrangements; 
   
xxii.   provide a report in draft form to the Oversight Group; and 
   
xxiii.   submit a final report in writing to the Department.  
 
4. Work Plan 
 
A recommended work plan for the Evaluation Group is set out below. This will be discussed in 
greater detail with the Evaluation Group. 
 
Task Timeframe for 
delivery 
Lead responsibility for 
delivery 
Teleconference Meeting to be held 
involving the Evaluation Group and the 
Oversight Group 
 
Such meetings to be hold as required 
during the evaluation process.  
Early September Evaluation Group and 
Oversight Group 
Review of relevant quantitative and 
qualitative information by the 
Evaluation Group  
September Evaluation Group 
Stakeholder consultation, including on-
site meetings in Ireland  
29 September – 
3 October 
Evaluation Group 
Provide Draft Report for consideration End October Evaluation Group 
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and feedback from the Oversight Group 
Feedback from Oversight Group Mid November Oversight Group 
Provide Final Report Early December Evaluation Group 
 
The Evaluation Group will hold meetings with stakeholders and visit a number of sites in 
Ireland. 
 
Cancer, Blood & Organs Policy Unit will support the work of the Evaluation Group and will 
arrange site visits and consultation with stakeholders. The Department’s Office of the CMO and 
the National Cancer Control Programme will also be available to support the work of the 
Evaluation Group. 
 
The Chair of the Evaluation Group will coordinate the activities of the Group and be responsible 
for the production of the evaluation report.  He will decide on the work plan for the individual 
members of the group, including attendance at site visits and meetings with stakeholders. 
 
 
 
5. Composition of Evaluation Group 
 
Dr Pádraig Warde (Chair) 
Interim Vice President of Clinical Programs 
& Quality Initiatives 
Cancer Care Ontario 
Princess Margaret Hospital 
610 University Avenue 
Toronto, ON M5G 2M9 
Canada 
Email: Padraig.Warde@rmp.uhn.on.ca 
 
Professor Alison Richardson 
Southampton General Hospital 
Mailpoint 11 
Tremona Road 
Email: alison.richardson@soton.ac.uk 
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Southampton  
SO16 6YD 
United Kingdom 
 
OR 
 
University of Southampton 
Faculty of Health Sciences 
Building 67 
Highfield 
Southampton 
SO17 1BJ 
United Kingdom 
 
 
 
 
 
 
 
 
Professor Harry de Koning 
Erasmus University Medical Centre 
P.O. Box 2040 
3000 CA Rotterdam 
The Netherlands 
h.dekoning@erasmusmc.nl 
 
 
6. Expenses of Evaluation Group 
 
Travel, accommodation and meal expenses incurred in carrying out the evaluation will be 
reimbursed by the Department of Health. 
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OVERSIGHT GROUP MEMBERSHIP 
 
 Tracey Conroy (Chair). Assistant Secretary, Acute Hospitals Policy Division, Department 
of Health 
 
 Dr Tony Holohan, Chief Medical Officer, Department of Health 
 
 Dr Siobhán O’Halloran, Chief Nursing Officer, Department of Health 
 
 Dr Susan O’Reilly, National Cancer Control Programme, HSE 
 
 Dr Deirdre Mulholland, Office of the CMO, Department of Health 
 
 Michael Conroy, Cancer, Blood & Organs Policy Unit, Department of Health 
 
 
 
 
 
ADVISORY GROUP MEMBERSHIP 
 
 
 Michael Conroy (Chair), Cancer, Blood & Organs Policy Unit, Department of Health 
 
 Keith Comiskey, Cancer, Blood & Organs Policy Unit, Department of Health 
 
 Dr Deirdre Mulholland, Office of the CMO, Department of Health 
 
 Dr Susan O’Reilly, National Cancer Control Programme, HSE 
 
 Dr Mary Hynes, National Cancer Control Programme, HSE 
 
 Fidelma MacHale, National Cancer Control Programme, HSE  
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Appendix 2  
 
 
A Strategy for Cancer Control in Ireland 2006 
Cancer Policy Indicators 
 
 
1. Percentage of the population who are smokers by age, sex and social class. 
 
Data on smoking prevalence is available from a HSE telephone survey since 2003. Overall 
smoking prevalence declined from 28% in 2003 to 21.5% at end 2013. 
 
Smoking rates have decreased for both genders and across all age groups since 2003.  The rate of 
smoking has decreased among most socioeconomic groups since 2003, with the highest smoking 
rates being in the lower socio economic groups (DE1 and C22), 25.9% and 24.6% respectively in 
2013. The higher economic group (AB3) had the lowest rate at 13.0% at December 2013. 
 
 
2. Percentage of the adult and childhood populations who are overweight or obese by age, 
sex and social class. 
 
The SLÁN survey (2007) found that 36% of respondent reported being overweight with 14% 
being obese. Men were more lilkely to report being overweight or obese. 
 
Consistent with international research, Body Mass Index (BMI) based on self-reported height 
and weight measurements provided an underestimation of the true prevalence of overweight and 
obesity. Based on measured data, higher percentages were overweight and obese. Approximately 
2 out of 3 adults were at an unhealthy (either overweight or obese) weight and almost one out of 
4 adults was obese in 2007. 
 
The Irish Longitudinal Study on Ageing (TILDA) 2009-2011 found that 36% of Irish over 50s 
are obese and a further 43% are overweight. 
 
The Growing up in Ireland survey found that in 2007/2008 (based on physical measurement) 
75% of nine-year-olds were defined as being of healthy BMI, 19% were overweight and 7% 
were obese. Girls are more likely to be defined as being overweight or obese. Also, there are 
pronounced social-class inequalities, with 19% of boys and 18% of girls from professional 
households being overweight/ obese, compared to 29% of boys and 38% of girls from semi- and 
unskilled social-class households.  
                                                 
1
  D: All semi skilled and unskilled manual workers; E: All those entirely dependent on the state long -term; those 
unemployed for period exceeding 6 months  
2
 C2: All skilled manual workers and those manual workers with responsibility for other people 
3
  A: Professional people, very senior managers in business and commerce, or top -level civil servants; 
B: Middle management executives in large organizations; Principal Officers in local government and civil service; 
top management or owners of small business concerns, education and service establishments  
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3. Percentage of the population who consume more than the recommended alcohol weekly 
limits by age, sex and social class. 
 
“Alcohol consumption in Ireland 2013” published by the Health Research Board indicates from 
survey results that more than 150,000 people are dependent drinkers, more than a 1.35 million 
are harmful drinkers according to WHO standards. Thirty per cent of people interviewed say that 
they experienced some form of harm as a result of their own drinking. The report also reveals 
that the respondents underestimate what they drink by about 60%. 
 
Furthermore, the rate of abstinence, defined as consuming no alcohol in the previous 12 months, 
was 20.6%. Almost two-thirds (63.9%) of males and half (51.4%) of females started drinking 
alcohol before the age of 18 years. 67 % of drinkers and 80% of male drinkers consumed six or 
more standard drinks on the occasion that they consumed the highest number of standard drinks 
in the last year. 
 
 
4. Incidence of major site-specific cancers, to include at a minimum lung, breast, prostate 
and colorectal cancer 
 
National Cancer Registry data on Cancer Incidence shows that incidence has been steadily 
increasing for total cancers from approx 15,000 in 2002 to 20,000 in 2012 (24,800 in 2002 to 
36,0004 in 2012 including non-melanoma skin cancers). Over half of this number is accounted 
for the four most common malignancies – prostate (3,400 cases in 2012), breast (2,800) 
colorectal (2,500) and lung (2,300). Time trends vary by cancer type; many increased during the 
period 2002 to 2012, but some have seen decreases, notably stomach cancer and male lung 
cancer. 
 
 
5. Incidence of invasive and in-situ melanoma 
 
National Cancer Registry data on Incidence of Invasive and in-situ melanoma shows that 
incidence is rising for both genders in the period from 2002 to 2012. Melanoma skin cancer has 
rised from 550 cases in 2002 to approx. 900 in 2012, while in-situ melanoma has risen from 220 
cases in 2002 to 500 in 2012 – incidence has increased in both genders, with the greatest increase 
in males. 
 
 
6. Uptake of screening and incidence of interval breast cancers in populations covered by 
BreastCheck.  
 
BreastCheck, the National Breast Screening Programme, is a population-based call re-call 
programme that offers women aged 50 to 64 a free mammogram every two years. Provisional 
uptake for 2013 is 70.9%. 
                                                 
4
 Data for 2012 was preliminary and incomplete at the time of the Cancer Strategy Evaluation 
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The BreastCheck interval cancer rate (based on National Cancer Registry data for interval 
cancers for women screened 2000-2007) is: 
 
  
 
First Round 
Subsequent Round – 
Initial Screening 
Subsequent Round – 
Subsequent 
Screening 
 
 
Total 
Total Interval 
Cancers Rate per 
10,000 negatively 
screened 
21.85 16.65 19.13 19.24 
 
 
7. Percentage of women in the target age-groups for whom population based cervical 
cancer screening is available. 
 
CervicalCheck, the National Cervical Screening Programme provides free smear tests through 
primary care settings to all of the approximately 1.2 million women aged 25-60 years that are 
eligible for screening. 
 
 
7a: Percentage of men and women in the target age-groups for whom population based 
colorectal cancer screening is available.       
 
BowelScreen, the National Bowel Screening Programme commenced in October 2012 with the 
ultimate aim of reducing mortality from colorectal cancer in men and women aged 55-74 in 
Ireland. The programme is being implemented on a phased basis commencing with men and 
women aged 60-69 years. The programe aims to complete the first round of screening to all 60-
69 year olds by end 2015. 
 
 
8. Percentage uptake of screening in areas covered by the Irish Cervical Screening 
Programme 
 
Coverage of women by age group in first 5 years of CervicalCheck. 
 
Age 
grou
p 
Number screened Eligible women % 
coverag
e 
25-29 148,136 187,408 79.0 
30-34 156,948 199,171 78.8 
35-39 142,933  182,024 78.5 
40-44 128,239 164,482 78.0 
45-49 114,211 153,669 74.3 
50-54 94,418 137,649 68.6 
55-59 78,628 122,401  64.2 
60 13,121 22,459  58.4 
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Total 876,634 1,169,263 75.0 
 
 
8a. Percentage uptake of screening for BowelScreen, the National Bowel Screening 
Programme. 
 
In 2013 there were 60,000 invitations issued. To end June 2014, 100,000 invitations have been 
issued and the Programme is on target to invite a total of 200,000 in the calendar year 2014. The 
first round of screening is on track for completion at the end of 2015, at which time all identified 
men and women aged 60-69 will have been invited to participate. Participation in the 
BowelScreen programme was in the region of 42% in 2013, and this will increase over time.   It 
is anticipated that participation will be around 50% by the end of the first screening round at the 
end of 2015. 
 
 
 
9. Stage of presentation of common cancers: appropriate stage indicators should be defined 
for lung, breast, colorectal and cervical cancers 
 
Data on stage of presentation for cancers is collected by the National Cancer Registry. Stage of 
presentation varied widely according to the cancer type, depending on a range of factors, e.g. 
diagnostic methods available. No discernable change in overall stage of presentation is visible 
over the period 2002 to 2012. However, the trend is towards earlier stage diagnosis for prostate, 
lung and non-melamona skin cancer.  
 
 
10. Percentage of patients with cancer whose care is consistent with national, 
multidisciplinary guidelines, as developed by HIQA 
 
The HSE compiles data showing compliance with a range of indicators based on the HIQA 
Quality Assurance Standards for Symptomatic Breast Disease Services. The HSE report 
measures a range of performance standards such as (i) access to diagnostic clinics and diagnotic 
procedures; (ii) the level of involvements of multidisciplinary meetings, (iii) time to treatment 
for surgery, radiation oncology and chemotherapy, etc. 
 
 
11. Trends in quality of life for cancer patients, determined by ongoing quality of life 
measurement, at different stages in the care pathway for major cancers. 
 
No “time trend” data is available. Some study has been carried out by the National Cancer 
Registry. 
 
 
12. Waiting times from diagnosis to definitive treatment for major cancer and 
13. Percentage of patients waiting for longer than one month from the time of diagnosis to 
the start of treatment 
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Approximately 35% of all cancers (excluding non-melanoma skin cancer) had tumour-directed 
treatment within 1 week from date of diagnosis between 2002 and 2011.  At one month this 
increased to approximately 65%, at three months to 88% and at six months to just under 95%. 
 
Approximately 43% of all Colorectal cases had tumour-directed treatment within 1 week from 
date of diagnosis between 2002 and 2011.  At one month this increased to approximately 74%, at 
three months to just under 97% and at six months to 99%. 
 
Approximately 17% of all Lung cases had tumour-directed treatment within 1 week from date of 
diagnosis between 2002 and 2011.  At one month this increased to approximately 54%, at three 
months to 89% and at six months to 97%. 
 
Approximately 14% of all Breast cases had tumour-directed treatment within 1 week from date 
of diagnosis between 2002 and 2011.  At one month this increased to approximately 77%, at 
three months to 98% and six months to 99%.  
 
The National Cancer Control Programme Symptomatic Breast Disease 3 year report 2010-2012 
shows that in that period, over 88% of patients had their surgery carried out within 4 weeks of 
the discussion of the management of their disease at a multidisciplinary meeting. 
 
 
14. Percentage of breast cancer patients undergoing therapeutic surgical procedures who 
do so in a designated breast cancer treatment centre 
 
Data from the National Cancer Registry shows the number of cases in each hospital of a tumour 
directed surgery or site specific principal surgical procedure. Data for Breast Cancer shows that 
following the reorganistaton of cancer surgery into the designated cancer centres, 100% of breast 
cancer surgery in the public sector was undertaken in the designated centres in 2010 and 2011. 
However, some 25% of total breast cancer surgery is carried out in the private sector. 
 
 
15. Survival rates: 
a. 5-year Relative Survival Rate for Breast Cancer 
b. 1-year Relative Survival Rate for Lung Cancer 
c. 5-year Relative Survival Rate for Prostate Cancer 
d. 5-year Relative Survival Rate for Colorectal Cancer 
 
Survival estimates for most cancers have improved over time, although the trend is clearer for 
some cancers than for others. Net survival to five years for all cancers (excl. non-melanoma skin 
cancer) increased from 45% for patients diagnosed during 1994-1999 to 59% for patients 
daignosed during 2008-2012. The greatest improvements have been seen for colorectal, breast, 
kidney, testicular and prostate cancers. Net survival over 70% to five years is recorded for 
melanoma skin (86%), hodgkin lymphoma (83%), thyroid (83%), bladder (73%), prostate (91%), 
testicular (96%), breast (81%). However, five year survial was very low (under 30%) for cancers 
of the lung, pancreas, liver, stomach, oesophagus and malignant brain. 
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16. Mortality rates: 
a. Direct Age Standardised Mortality rate (5-year, all ages) for all causes of cancer 
b. Direct Age Standardised Mortality rates (5-year, all ages) for the top six causes of cancer 
mortality 
 
Cancer is the second most common casue of death in Ireland with 7,900 to 8,800 deaths per 
annum in the period from 2007 to 2012. However, the annual rate of cancer mortaity decesead 
significantly for both males and females in the period 1994-2012 largely due to improved 
treatments and earlier diagnosis.  
 
Lung cancer remains the highest cause of death from cancer for both men and women with 
approximately 1,700 to 1,900 cases in total from 1994 to 2012. Age standardised mortaity rates 
for men have decreased; however, female lung cancer death rates are continuing to rise. 
Mortality from colorectal cancer is decreasing for both men and women due in part to advances 
in treatment surgery over the last two decades. The prognosis for breat cancer has improved 
since the 1990s due to earlier diagnosis and treatment advances and mortality rates have 
decreased by almost 2% annually from 1994-2012. While prostate cancer incidence rates have 
increased dramatically, mortality rates have decreased.  
 
 
17. Percentage of cancer patients seen by a member of a Specialist Palliative Care Team 
 
Data not available 
 
 
18. Percentage of cancer patients dying by place of death (home, hospice, hospital) 
 
In the period from 2002 to 2012, about 40% of cancer deaths took place in acute hospitals, with 
about 10% of these being in private hospitals. The percentage of deaths in hospices has increased 
from 14% to 18% in the period. The proportion of pateints dying at home has remained relatively 
stable at around 26% in the period. The number of patients dying in community and district 
homes has reduced from around 9% to 6% in 2012. 
 
 
19. Percentage of cancer patients participating in clinical trials  
 
Data on the total number of patients participating in clinical trials is not available. However, the 
Irish Cooperative Oncology Research Group (ICORG) provides information on the number of 
patients participating in its clinical trials. ICORG is majority funded by the Health Research 
Board with a grant from ther Irish Cancer Society. 
 
More than 1,600 new patients enrolled with ICORG in 2013 and there are more than 4,000 
patients under active surveillance on treatment or in follow-up. ICORG had more than 70 open 
trials in 2013. ICORG’s membership of international collaborative groups continues to grow. 
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Appendix 3 
List of Groups/People met by Evaluation Team 
 
Department of Health 
Minister for Health 
Office of the Chief Medical Officer 
Office of the Chief Nursing Officer 
Acute Hospitals Division 
Tobacco & Alcohol Unit 
Health Promotion Unit 
Health & Wellbeing Programme 
Palliative Care Unit 
 
HSE National Cancer Control Programme 
Director 
National Surgical Oncology Programme 
National Medical Oncology & Haematology Programme  
National Radiation Oncology Programme  
Community Oncology & Primary Care & Prevention 
 
Other HSE Officials 
Director General 
National Screening Service 
Acute Services Division 
Clinical Strategy & Programmes 
Palliative Care Programme 
Quality and Patient Safety Division 
Transformation Programme 
Nursing & Midwifery Planning & Development Unit  
Public Health Nursing and Community Oncology  
 
St James’s Hospital 
Senior clinicians and senior management  
 
Cork University Hospital 
Senior clinicians and senior management 
 
National Cancer Registry 
Interim Director 
 
Medical Colleges 
Royal College of Surgeons in Ireland 
Royal College of Physicians of Ireland 
Irish College of General Practitioners 
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Irish Association for Nurses in Oncology 
President 
 
Health Research Board 
Director of Funding Programme 
Head of Clinical and Applied Biomedical Research  
 
Hereditary Cancer 
Director, National Centre for Medical Genetics, Crumlin  
Medical Oncologist and Medical Geneticist, Mater Private Hospital 
 
Irish Clinical Oncology Research Group 
Clinical Leader 
 
Marymount Hospice 
Senior clinicians and senior management 
 
All Ireland Institute for Hospice and Palliative Care 
Director 
 
Hospice Foundation 
Director  
 
Voluntary Hospice Group 
Chair of the Voluntary Hospice Group  
 
Principal Cancer Charities 
Irish Cancer Society  
Marie Keating Foundation 
Europa Donna 
Cancer Care West 
ARC Cancer Support Centre 
 
  
 
 
  
55 
 
Appendix 4 
 
List of Documents reviewed by Evaluation Team 
 
Documents 
A Strategy for Cancer Control in Ireland 2006 
Policy Indicators for 2006 Strategy for Cancer Control 
Data for Policy Indicators from 2006 Strategy 
Healthy Ireland 
The Establishment of Hospital Groups as a transition to Independent Hospital Trusts 
Briefing on Health Identifiers Act 
7-Year National Cancer Control Programme Report 
Patient Engagement Activities NCCP October 2014 
Final Full Suite of NCCP KPIs - Sept 2014  
ICORG Activity Report Jan-Dec 2013 
ICORG Activity Report Jan-Jun 2014 
Health Research Board Annual Report 2012 
Final National Histopathology QA Programme Implementation Report 2014 
HIQA National Standards for Safer Better Healthcare 
Irish Cancer Society Strategy Statement 2013-2017 
Childhood Cancer Trends Report July 2014 
Medical Oncology Strategy review Oct 2014 
National Cancer Registry Prostate Cancer Report 
Notes on QA programme Meeting with Evaluation Team 
QA Programmes Summary Oct 2014 
 
Dept. of Health Presentations  
Cancer Policy in Ireland  
Diet and Cancer  
Healthy Ireland - Health & Wellbeing Programme  
Palliative Care Policy  
Tobacco & Alcohol Control 
 
Other Presentations 
Summary of NCCP progress to date  
Medical Oncology Strategy review 
NCCP Patient Engagement activities 
NCCP Community oncology update 
Cancer Screening  
A Strategy and Education Framework for nurses caring for people with cancer in Ireland 
Nursing Strategy Update 
Marymount Hospice  
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Appendix 5 
 
Evaluation Panel report on the implementation of the 55 Recommendations of the 2006 Cancer 
Control Programme. November 2014 
 
 
 
 RECOMMENDATION  FULLY/LARGELY IMPLEMENTED PARTIALLY IMPLEMENTED NOT IMPLEMENTED NO INFORMATION/NOT 
REVIEWED 
1 A third National Cancer Forum 
should be appointed by the 
Minister with terms of reference 
and composition reflecting the 
changed health system.   
  X  
2 The recommendations of the 
Review of the National Health 
Promotion Strategy, 2004 should 
be implemented across all sectors.   
X     
3 Compliance with all provisions of 
the Public Health (Tobacco) Acts, 
2002 and 2004 should be 
monitored.  
X    
4 Excise duty on cigarettes should be 
substantially increased each year 
above the rate of inflation.  To this 
end the National Cancer Forum 
should produce a pre – Budget 
submission to the Minister for 
Finance each year in order to 
continue advocating for price 
increases on tobacco.   
X    
5 Nicotine replacement therapy 
should be made available free of 
charge to all medical card holders.   
X    
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 RECOMMENDATION  FULLY/LARGELY IMPLEMENTED PARTIALLY IMPLEMENTED NOT IMPLEMENTED NO INFORMATION/NOT 
REVIEWED 
6 The Report of the Strategic Task 
Force on Alcohol, 2002 should be 
implemented in full.   
   
X  
 
7 The recommendations of the 
Report of the National Task Force 
on Obesity, 2005 should be 
implemented in full.  In particular, 
there is a need for measures that 
raise the awareness of the links 
between diet and cancer.   
 X   
8 The health services should work 
with the food industry in order to 
encourage it to produce, market 
and improve access to attractive 
and healthy options.   
 x   
9 The recommendations of the 
Report of the National Task Force 
on Obesity, 2005 in relation to 
physical activity should be 
implemented in full.   
 x   
10 In conjunction with campaigners to 
promote safe sun practices and to 
reduce exposure to ultraviolet 
radiation, regulation of sunbed 
use, including restriction to use by 
adults only, should be put in place.   
x    
11 The public should be made aware 
that radon measurements can be 
undertaken by the Radiological 
Protection Institute of 
Ireland.  Consideration should be 
given to providing financial 
support for testing in high-radon 
x    
58 
 
 RECOMMENDATION  FULLY/LARGELY IMPLEMENTED PARTIALLY IMPLEMENTED NOT IMPLEMENTED NO INFORMATION/NOT 
REVIEWED 
areas and for any necessary 
remedial work, on a means-tested 
basis.  
12 The HSE should put in place 
arrangements to monitor 
inequalities in cancer risks, cancer 
occurrence, cancer services and 
cancer outcomes.   
 x   
13 Population-based screening 
programmes should only be 
introduced where their population 
health benefit can be 
demonstrated using the National 
Cancer Forum criteria. 
x    
14 Breast screening should be 
extended to include all women 
aged between 50 and 69.   
x    
15 The national roll-out of the Irish 
Cervical Screening Programme 
should be completed as a matter 
of priority.   
x    
16 A colorectal cancer programme 
should be established to 
encompass population screening, 
high risk screening and necessary 
developments in symptomatic 
colorectal cancer services.  In 
preparation for this programme, 
the Department of Health and 
Children should establish a 
working group under aegis of the 
National Cancer Forum to address 
a range of implementation issues.   
 x   
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 RECOMMENDATION  FULLY/LARGELY IMPLEMENTED PARTIALLY IMPLEMENTED NOT IMPLEMENTED NO INFORMATION/NOT 
REVIEWED 
17 The Department of Health and 
Children in conjunction with the 
HSE and BreastCheck should plan 
the alignment of population-based 
screening programmes. 
x    
18 Population-based prostate 
screening should NOT be 
introduced in Ireland at present.  
The National Cancer Forum should 
keep emerging international 
evidence on population screening 
for prostate cancer under review.     
x    
19 Opportunistic testing of 
asymptomatic individuals for 
cancer is not recommended.    
 X   
20 The HSE should develop specific 
programmes that promote early 
detection of cancer.   
 X   
21  All cancer care should be delivered 
through a national system of four 
Managed Cancer Control 
Networks, each serving a 
population of approximately one 
million people. 
X    
22 A Network Director should be 
appointed by the HSE as soon as 
possible to each Managed Cancer 
Control Network to support and 
direct implementation of cancer 
policy.  
X    
23 A lead clinician for each Cancer 
Centre should be appointed.  In 
addition, a clinician should be 
 X   
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 RECOMMENDATION  FULLY/LARGELY IMPLEMENTED PARTIALLY IMPLEMENTED NOT IMPLEMENTED NO INFORMATION/NOT 
REVIEWED 
appointed to lead the 
development of cancer care 
pathways for each major site 
specific cancer in partnership with 
all stakeholders within the 
network.  The Cancer Control 
Network Director should head this 
team of lead clinicians.  
24 The HSE should develop care 
pathways for cancer care to link 
primary care services, hospital 
services and other relevant 
services.   
 X   
25 Improved cancer information 
services should be available to 
primary care.   
 X   
26 The HSE should develop 
programmes that support primary 
care professionals in the provision 
of cancer services.    
 X   
27 The HSE should ensure that 
systems are in place to identify 
and support a ‘designated health 
professional’ as a contact person 
for each individual cancer patient 
who may require it.   
  x  
28 Cancer Centres that each serve a 
minimum population of 500,000 
should be designated by the HSE 
as soon as possible.  Ireland will 
require about eight such centres.  
x    
29 The HSE should conduct a needs 
assessment for cancer services 
 X   
61 
 
 RECOMMENDATION  FULLY/LARGELY IMPLEMENTED PARTIALLY IMPLEMENTED NOT IMPLEMENTED NO INFORMATION/NOT 
REVIEWED 
with a particular emphasis on 
hospital-based cancer treatment 
that addresses the need for 
continued expansion in capacity 
and maximises the use of 
ambulatory care.   
30 The National Network for 
Radiation Oncology Services 
should be established by the HSE 
in accordance with the timelines 
set by Government.   
X    
31 Patients should have their 
diagnosis established and their 
treatment planned by site-specific 
multidisciplinary teams.   
X    
32 The HSE should conduct a review 
of the number of centres required 
for the management of 
symptomatic breast disease to 
bring them into line with 
designated Cancer Centres.    
x    
33 The HSE should conduct a national 
needs assessment for rare cancers.   
x    
34 A National Cancer Genetics Policy 
should be developed by the 
National Cancer Forum.  
  x  
35 The HSE should ensure that each 
Managed Cancer Centre Control 
Network has a comprehensive 
specialist palliative care service.   
  X  
36 A formal linkage should be 
established between the National 
Cancer Forum and the National 
   x 
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 RECOMMENDATION  FULLY/LARGELY IMPLEMENTED PARTIALLY IMPLEMENTED NOT IMPLEMENTED NO INFORMATION/NOT 
REVIEWED 
Council for Specialist Palliative 
Care.   
37 The HSE should ensure that access 
to comprehensive psycho-
oncology and psychosocial support 
is provided for cancer patients and 
their families in each Managed 
Cancer Control Network.   
  x  
38 A partnership framework should 
be developed between the HSE 
and the voluntary sector.   
  X  
39 A code of practice should be 
developed for self-help groups, 
support groups and support 
centres.   
X    
40  HIQA should establish a National 
Framework for Quality in Cancer 
Control.   
 X   
41 HIQA should establish site-specific 
multidisciplinary groups at a 
national level to develop 
guidelines for quality in major 
cancers.   
X     
42 HIQA should develop a system of 
licensing and accreditation of 
Cancer Centres and services that 
should apply to both the public 
and private sectors.  The systems 
of licensing and accreditation 
should be given statutory effect.   
  X  
43 HIQA should develop a cancer 
surveillance system that will build 
on the existing system of cancer 
 X   
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 RECOMMENDATION  FULLY/LARGELY IMPLEMENTED PARTIALLY IMPLEMENTED NOT IMPLEMENTED NO INFORMATION/NOT 
REVIEWED 
registration.   
44 Mandatory notification of cancer 
should be put in place through 
appropriate legislation.   
  X  
45 HIQA should ensure that a 
minimum national dataset should 
be collected for all cases of cancer.   
  X  
46 HIQA should ensure that the public 
has access to high-quality up to 
date information about all aspects 
of cancer.   
 X   
47 General practitioners should have 
comprehensive information that 
enables informed referral and 
other management decisions.    
 X   
48 Information systems and 
information technology should be 
developed by the HSE to support 
the management and delivery of 
cancer services.    
 X   
49 HIQA should establish a Cancer 
Health Technology Assessment 
Panel.   
 X   
50 The HSE should develop a National 
Cancer Workforce Plan designed to 
fully implement national cancer 
policy.  
  X  
51 The third National Cancer Forum, 
in partnership with the HRB, 
should advise on the development 
of a specific plan for cancer 
research.  
  X  
52 There should be improved clinical  X   
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 RECOMMENDATION  FULLY/LARGELY IMPLEMENTED PARTIALLY IMPLEMENTED NOT IMPLEMENTED NO INFORMATION/NOT 
REVIEWED 
trial entry for patients, both in 
terms of the number of trials 
conducted and the enrolment to 
them.   
53 Ireland should establish a national 
tissue bio bank to support research 
and service delivery.   
  X  
54 The HRB should establish a 
national cancer research database.   
  X  
55 The HSE should present a report 
on policy indicators each year to 
the National Cancer Forum.   
 X   
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A Strategy for Cancer Control in Ireland 2006 
Cancer Policy Indicators 
 
 
1. Percentage of the population who are smokers by age, sex and social class. 
 
Data on smoking prevalence is available from a HSE telephone survey since 2003. Overall smoking prevalence declined from 28% in 2003 to 
21.5% at end 2013. 
 
Smoking rates have declined across the majority of age groups since 2003, with the largeest reductions seen in the 18-24 and 25-34 age groups. 
However, these two age groups still have the highest rates of smoking prevalance at 30.7% and 28.1% respectively at December 2013. 
 
Smoking rates have decresaed for both genders since 2003.  Rates for men have declined to 22.85% at end 2013, with 20.2% of women reporting 
being smokers. 
 
The rate of smoking has decreased among most socioeconomic groups since 2003, with the highest smoking rates being in DE and C2, 25.9% 
and 24.6% respectively. The AB group had the lowest rate at 13.0% at December 2013. 
 
 
2. Percentage of the adult and childhood populations who are overweight or obese by age, sex and social class. 
 
The SLÁN survey (2007) found that 36% of respondent reported being overweight with 14% being obese. Men were more lilkely to report being 
overweight or obese. 
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Consistent with international research, Body Mass Index (BMI) based on self-reported height and weight measurements provided an 
underestimation of the true prevalence of overweight and obesity. Based on measured data, higher percentages were overweight and obese. 
Approximately 2 out of 3 adults were at an unhealthy (either overweight or obese) weight. Almost one out of 4 adults was obese in 2007. 
 
The Irish Longitudinal Study on Ageing (TILDA) found that 36% of Irish over 50s are obese and a further 43% are overweight. 
 
The Growing up in Ireland survey found that 75% of nine-year-olds were defined as being of healthy BMI, 19% were overweight and 7% were 
obese. Girls are more likely to be defined as being overweight or obese. Also, there are pronounced social-class inequalities, with 19% of boys 
and 18% of girls from professional households being overweight/ obese, compared to 29% of boys and 38% of girls from semi- and unskilled 
social-class households.  
 
 
3. Percentage of the population who consume more than the recommended alcohol weekly limits by age, sex and social class. 
 
“Alcohol consumption in Ireland 2013” published by the Health Research Board indicates that more than 150,000 people are dependent drinkers, 
more than a 1.35 million are harmful drinkers according to WHO standards. Thirty per cent of people interviewed say that they experienced 
some form of harm as a result of their own drinking. The report also reveals that the respondents underestimate what they drink by about 60%. 
 
Furthermore, the rate of abstinence, defined as consuming no alcohol in the previous 12 months, was 20.6%. Almost two-thirds (63.9%) of 
males and half (51.4%) of females started drinking alcohol before the age of 18 years. 67 % of drinkers and 80% of male drinkers consumed six 
or more standard drinks on the occasion that they consumed the highest number of standard drinks in the last year. 
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4. Incidence of major site-specific cancers, to include at a minimum lung, breast, prostate and colorectal cancer 
 
National Cancer Registry data on Cancer Incidence shows that incidence has been steadily increasing for total cancers from approx 15,000 in 
2002 to 20,000 in 2012 (24,800 in 2002 to 36,0005 in 2012 including non-melanoma skin cancers). Over half of this number is accounted for the 
four most common malignancies – prostate (3,400 cases in 2012), breast (2,800) colorectal (2,500) and lung (2,300). Time trends vary by cancer 
type; many increased during the period 2002 to 2012, but some have seen decreases, notably stomach cancer and male lung cancer. 
 
 
5. Incidence of invasive and in-situ melanoma 
 
National Cancer Registry data on Incidence of Invasive and in-situ melanoma shows that incidence is rising for both genders in the period from 
2002 to 2012. Melanoma skin cancer has rised from 550 cases in 2002 to approx. 900 in 2012, while in-situ melanoma has risen from 220 cases 
in 2002 to 500 in 2012 – incidence has increased in both genders, with the greatest increase in males. 
 
 
6. Uptake of screening and incidence of interval breast cancers in populations covered by BreastCheck.  
 
BreastCheck, the National Breast Screening Programme, is a population-based call re-call programme that offers women aged 50 to 64 a free 
mammogram every two years. Provisional uptake for 2013 is 70.9%. 
 
The BreastCheck interval cancer rate (based on National Cancer Registry data for interval cancers for women screened 2000-2007) is: 
                                                 
5
 Data for 2012 was preliminary and incomplete at the time of the Cancer Strategy Evaluation  
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First Round 
Subsequent Round 
– Initial Screening 
Subsequent Round 
– Subsequent 
Screening 
 
 
Total 
Total Interval 
Cancers Rate per 
10,000 negatively 
screened 
21.85 16.65 19.13 19.24 
 
 
7. Percentage of women in the target age-groups for whom population based cervical cancer screening is available. 
 
CervicalCheck, the National Cervical Screening Programme provides free smear tests through primary care settings to all of the approximately 
1.2 million women aged 25-60 years that are eligible for screening. 
 
 
7a: Percentage of men and women in the target age-groups for whom population based colorectal cancer screening is available 
 
BowelScreen, the National Bowel Screening Programme commenced in October 2012 with the ultimate aim of reducing mortality from 
colorectal cancer in men and women aged 55-74 in Ireland. The programme is being implemented on a phased basis commencing with men and 
women aged 60-69 years. The programe aims to complete the first round of screening to all 60-69 year olds by end 2015. 
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8. Percentage uptake of screening in areas covered by the Irish Cervical Screening Programme 
 
Coverage of women by age group in first 5 years of CervicalCheck. 
 
Age group Number screened Eligible women % coverage 
25-29 148,136 187,408 79.0 
30-34 156,948 199,171 78.8 
35-39 142,933  182,024 78.5 
40-44 128,239 164,482 78.0 
45-49 114,211 153,669 74.3 
50-54 94,418 137,649 68.6 
55-59 78,628 122,401  64.2 
60 13,121 22,459  58.4 
Total 876,634 1,169,263 75.0 
 
 
8a. Percentage uptake of screening for BowelScreen, the National Bowel Screening Programme. 
 
In 2013 there were 60,000 invitations issued. To end June 2014, 100,000 invitations have been issued and the Programme is on target to invite a 
total of 200,000 in the calendar year 2014. The first round of screening is on track for completion at the end of 2015, at which time all identified 
men and women aged 60-69 will have been invited to participate. Participation in the BowelScreen programme was in the region of 42% in 
2013, and this will increase over time.   It is anticipated that participation will be around 50% by the end of the first screening round at the end of 
2015. 
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9. Stage of presentation of common cancers: appropriate stage indicators should be defined for lung, breast, colorectal and cervical 
cancers 
 
Data on stage of presentation for cancers is collected by the National Cancer Registry. Stage of presentation varied widely according to the 
cancer type, depending on a range of factors, e.g. diagnostic methods available. No discernable change in overall stage of presentation is visible 
over the period 2002 to 2012. However, the trend is towards earlier stage diagnosis for prostate, lung and non-melamona skin cancer.  
 
 
10. Percentage of patients with cancer whose care is consistent with national, multidisciplinary guidelines, as developed by HIQA 
 
The HSE compiles data showing compliance with a range of indicators based on the HIQA Quality Assurance Standards for Symptomatic Breast 
Disease Services. The HSE report measures a range of performance standards such as (i) access to diagnostic clinics and diagnotic procedures; 
(ii) the level of involvements of multidisciplinary meetings, (iii) time to treatment for surgery, radiation oncology and chemotherapy, etc. 
 
 
11. Trends in quality of life for cancer patients, determined by ongoing quality of life measurement, at different stage s in the care 
pathway for major cancers. 
 
No “time trend” data is available. Some study has been carried out by the National Cancer Registry. 
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12. Waiting times from diagnosis to definitive treatment for major cancer and 
13. Percentage of patients waiting for longer than one month from the time of diagnosis to the start of treatment 
 
Approximately 35% of all cancers (excluding non-melanoma skin cancer) had tumour-directed treatment within 1 week from date of diagnosis 
between 2002 and 2011.  At one month this increased to approximately 65%, at three months to 88% and at six months to just under 95%. 
 
Approximately 43% of all Colorectal cases had tumour-directed treatment within 1 week from date of diagnosis between 2002 and 2011.  At one 
month this increased to approximately 74%, at three months to just under 97% and at six months to 99%. 
 
Approximately 17% of all Lungcases had tumour-directed treatment within 1 week from date of diagnosis between 2002 and 2011.  At one 
month this increased to approximately 54%, at three months to 89% and at six months to 97%. 
 
Approximately 14% of all Breast cases had tumour-directed treatment within 1 week from date of diagnosis between 2002 and 2011.  At one 
month this increased to approximately 77%, at three months to 98% and six months to 99%. 
 
 
14. Percentage of breast cancer patients undergoing therapeutic surgical procedures who do so in a designated breast cancer treatment 
centre 
 
Data from the National Cancer Registry shows the number of cases in each hospital of a tumour directed surgery or site specific principal 
surgical procedure. Data for Breast Cancer shows that following the reorganistaton of cancer surgery into the designated cancer centres, 100% of 
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breast cancer surgery in the public sector was undertaken in the designated centres in 2010 and 2011. However, some 25% of total breast cancer 
surgery is carried out in the private sector. 
 
 
15. Survival rates: 
a. 5-year Relative Survival Rate for Breast Cancer 
b. 1-year Relative Survival Rate for Lung Cancer 
c. 5-year Relative Survival Rate for Prostate Cancer 
d. 5-year Relative Survival Rate for Colorectal Cancer 
 
Survival estimates for most cancers have improved over time, although the trend is clearer for some cancers than for others. Net survival to five 
years for all cancers (excl. non-melanoma skin cancer) increased from 45% for patients diagnosed during 1994-1999 to 59% for patients 
daignosed during 2008-2012. The greatest improvements have been seen for colorectal, breast, kidney, testicular and prostate cancers. Net 
survival over 70% to five years is recorded for melanoma skin (86%), hodgkin lymphoma (83%), thyroid (83%), bladder (73%), prostate (91%), 
testicular (96%), breast (81%). However, five year survial was very low (under 30%) for cancers of the lung, pancreas, liver, stomach, 
oesophagus and malignant brain. 
 
 
16. Mortality rates: 
a. Direct Age Standardised Mortality rate (5-year, all ages) for all causes of cancer 
b. Direct Age Standardised Mortality rates (5-year, all ages) for the top six causes of cancer mortality 
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Cancer is the second most common casue of death in Ireland with 7,900 to 8,800 deaths per annum in the period from 2007 to 2012. However, 
the annual rate of cancer mortaity decesead significantly for both males and females in the period 1994-2012 largely due to improved treatments 
and earlier diagnosis.  
 
Lung cancer remains the highest cause of death from cancer for both men and women with approximately 1,700 to 1,900 cases in total from 
1994 to 2012. Age standardised mortaity rates for men have decreased; however, female lung cancer death rates are continuing to rise. Mortality 
from colorectal cancer is decreasing for both men and women due in part to advances in treatment surgery over the last two decades. The 
prognosis for breat cancer has improved since the 1990s due to earlier diagnosis and treatment advances and mortality rates have decreased by 
almost 2% annually from 1994-2012. While prostate cancer incidence rates have increased dramatically, mortality rates have decreased.  
 
 
17. Percentage of cancer patients seen by a member of a Specialist Palliative Care Team 
 
Data not available 
 
 
18. Percentage of cancer patients dying by place of death (home, hospice, hospital) 
 
In the period from 2002 to 2012, about 40% of cancer deaths took place in acute hospitals, with about 10% of these being in private hospitals. 
The percentage of deaths in hospices has increased from 14% to 18% in the period. The proportion of pateints dying at home has remained 
relatively stable at around 26% in the period. The number of patients dying in community and district homes has reduced from around 9% to 6% 
in 2012. 
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19. Percentage of cancer patients participating in clinical trials 
 
Data on the total number of patients participating in clinical trials is not available. However, the Irish Cooperative Oncology Research Group 
(ICORG) provides information on the number of patients participating in its clinical trials. ICORG is majority funded by the Health Research 
Board with a grant from ther Irish Cancer Society. 
 
More than 1,600 new patients enrolled with ICORG in 2013 and there are more than 4,000 patients under active surveillance on treatment or in 
follow-up. ICORG had more than 70 open trials in 2013. ICORG’s membership of international collaborative groups continues to grow. 
 
 
